CNTB Connect Biopharma Holdings Limited

17
+0.6  (+4%)
Previous Close 16.4
Open 16.52
52 Week Low 15.2909
52 Week High 23.2899
Market Cap $977,570,975
Shares 57,504,175
Float 57,504,175
Enterprise Value $943,068,470
Volume 12,720
Av. Daily Volume 0
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
CBP-174
Healthy adults
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
CBP-201
Atopic dermatitis
Phase 2b
Phase 2b
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
CBP-307
Ulcerative Colitis
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
CBP-201
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Phase 2
Phase 2
Phase 2 trial to be initiated 1H 2021.
CBP-201
Asthma
Phase 2
Phase 2
Phase 2 trial to be initiated 1H 2021.

Latest News

  1. SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-201 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

    The global, randomized, double-blind, placebo-controlled, dose-ranging clinical trial to assess the efficacy, safety, and pharmacokinetics (PK) profile of CBP-201, was designed to enroll 220 subjects and is being conducted…

    SAN DIEGO and TAICANG, China, April 08, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it has completed full enrollment of the phase 2 clinical trial evaluating CBP-201 in adult patients with moderate-to-severe Atopic Dermatitis (AD).

    The global, randomized, double-blind, placebo-controlled, dose-ranging clinical trial to assess the efficacy, safety, and pharmacokinetics (PK) profile of CBP-201, was designed to enroll 220 subjects and is being conducted at 60 sites across the US, China, Australia, and New Zealand. CBP-201 or placebo was administered to eligible adult subjects with moderate-to-severe AD for 16 weeks with 8 weeks of follow up (NCT04444752).

    "The completion of enrollment of the CBP-201 global phase 2 trial in patients with moderate-to-severe AD is an important step for Connect and our lead clinical program," said Zheng Wei, PhD, Co-founder and CEO of Connect Biopharma. "A significant unmet need still exists for patients and we believe that CBP-201 has the potential to show a differentiated profile to address it. We are optimistic that the results from this study, expected in the second half of this year, will continue to support our hypothesis."

    About Atopic Dermatitis

    Atopic dermatitis (AD), which has an estimated lifetime prevalence of up to 20% and is increasing globally, is the most commonly diagnosed chronic inflammatory skin disorder. It is characterized by skin barrier disruption and immune dysregulation. It is estimated that 26.1 million people in the United States have AD, of which 6.6 million have moderate-to-severe disease. It is estimated that over 58% of adults with moderate-to-severe AD have disease which physicians consider to be inadequately controlled by approved therapeutic modalities, including topical anti-inflammatory agents and systemic agents.

    About CBP-201

    CBP-201 is a novel IL-4Rα monoclonal antibody that has shown a favorable safety and efficacy profile in a Phase 1b clinical trial in adult patients with moderate-to-severe AD. CBP-201 was shown to be well tolerated with no new safety signals compared to other approved IL-4Rα blockers, and no reported injection site reactions or conjunctivitis. The proportion of patients given CBP-201 150mg or 300 mg or placebo, weekly for 4 weeks, who achieved an Investigator Global Assessment score of clear or almost clear skin (IGA 0,1) was 50%, 42.9% and 12.5% respectively. Additionally, skin lesion improvements were rapid, as evidenced as early as one week after dosing and were correlated with a rapid reduction in pruritus intensity and frequency. This suggests the potential for a differentiated efficacy profile, with fast onset of action for CBP-201 compared with data from clinical trials of the current biologic standard of care therapy.

    About Connect Biopharma Holdings Limited

    Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

    Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma. Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1). Specifically, we are developing CBP-307 for two types of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD).

    With current headquarters in China, additional operations in the United States and Australia, and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich global pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. For additional information about Connect Biopharma, please visit our website at www.connectbiopharm.com.

    FORWARD-LOOKING STATEMENTS

    Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential," "continue" or "project" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company's statements regarding the potential of CBP-201 to achieve a differentiated profile to address the unmet needs of patients with AD and the timing of the results of the Company's phase 2 clinical trial evaluating CBP-201 in adult patients with moderate-to-severe AD. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in the Connect Biopharma business and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"). Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Connect Biopharma undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharma's filings with the SEC which are available from the SEC's website (www.sec.gov) and on Connect Biopharma's website (www.connectbiopharm.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    IR/PR Contacts:

    Lazar FINN Partners

    David Carey (IR)

    T: +1-(212) 867-1768

    Erich Sandoval (Media)

    T: +1-(917)-497-2867

    Corporate Contacts:



    Primary Logo

    View Full Article Hide Full Article
  2. Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited.

    Connect Biopharma Holdings Limited (NASDAQ:CNTB), is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell- driven inflammatory diseases with a core expertise in the use of functional cellular assays with T cells to screen discovering potent product candidates against immune targets.*

    "We are pleased to be appointed as depositary bank for Connect Biopharma Holdings Limited's NASDAQ-listed Level III American Depositary Receipt program," said Daniel Clark, Global Head of Depositary Receipts at Deutsche Bank. "We look forward to providing…

    Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited.

    Connect Biopharma Holdings Limited (NASDAQ:CNTB), is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell- driven inflammatory diseases with a core expertise in the use of functional cellular assays with T cells to screen discovering potent product candidates against immune targets.*

    "We are pleased to be appointed as depositary bank for Connect Biopharma Holdings Limited's NASDAQ-listed Level III American Depositary Receipt program," said Daniel Clark, Global Head of Depositary Receipts at Deutsche Bank. "We look forward to providing dedicated client service and investor relations support to help drive the program's future success."

    In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services.

    Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings.

    * This information was provided by Connect Biopharma Holdings Limited (March 2021).

    Depositary Receipt Information

    Country

    China (Cayman Islands incorporated)

    Custodian Bank

    Deutsche Bank AG, Hong Kong Branch

    Effective Date

    March 23, 2021

     

     

    Level III ADR

     

    CUSIP

    207523 101

    ISIN

    US2075231017

    Symbol

    CNTB

    Exchange

    NASDAQ

    Current Ratio

    1 ADS: 1 Class A ordinary share

    Eligibility

    DTC

     

     

     

     

     

    Depositary Receipt Contacts

    Head of Depositary Receipts

    New Business Development

    Daniel Clark

    William Ng

    Tel: +44 (0) 20 7541 6888

    Tel: +852 2203 7889

     

     

    www.adr.db.com

    Markets Distribution

    London

     

    Tel: +44 (0) 20 7547 6500

    gtb.db.com

    New York

     

    Tel: +1 212 250 9100

     

    Hong Kong

     

    Tel: +852 2203 7854

    Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany's leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific.

    The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© March 2021 Deutsche Bank AG. All rights reserved.

    View Full Article Hide Full Article
  3. SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T-cell-driven research, today announced the closing of its initial public offering of 12,937,500 American Depositary Shares ("ADSs"), representing 12,937,500 ordinary shares of the Company, at a public offering price of US$17.00 per ADS.

    The number of ADSs issued at closing included the exercise in full of the underwriters' option to purchase 1,687,500 additional ADSs from the Company at the initial public offering price, less underwriting…

    SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T-cell-driven research, today announced the closing of its initial public offering of 12,937,500 American Depositary Shares ("ADSs"), representing 12,937,500 ordinary shares of the Company, at a public offering price of US$17.00 per ADS.

    The number of ADSs issued at closing included the exercise in full of the underwriters' option to purchase 1,687,500 additional ADSs from the Company at the initial public offering price, less underwriting discounts and commissions. The gross proceeds from the offering were approximately US$219.9 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. Each ADS represents one ordinary share of the Company. The ADSs began trading on the Nasdaq Global Market on March 19, 2021 under the ticker symbol "CNTB".

    Jefferies LLC, SVB Leerink LLC, Piper Sandler & Co. and China International Capital Corporation Hong Kong Securities Limited acted as joint book-running managers for the offering.

    A registration statement relating to the securities sold in this offering was declared effective by the U.S. Securities and Exchange Commission on March 18, 2021. This offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from (i) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 1-877-821-7388, or by email at ; (ii) SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, telephone: 1-800-808-7525 ex. 6105 or email: ; (iii) Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at 1-800-747-3924, or by e-mail at ; or (iv) China International Capital Corporation Hong Kong Securities Limited, Address: 29th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong, by telephone at 852-2872-2000 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Connect Biopharma Holdings Limited

    Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research.

    Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα), which is a validated target for the treatment of several inflammatory diseases such as atopic dermatitis (AD) and asthma.

    Our second lead product candidate is CBP-307, a modulator of a T cell receptor known as sphingosine 1-phosphate receptor 1 (S1P1).

    IR/PR Contacts: 

    Lazar FINN Partners

    David Carey (IR)

    T: +1-(212) 867-1768





    Erich Sandoval (Media)

    T: +1-(917)-497-2867

    Corporate Contacts:



    Primary Logo

    View Full Article Hide Full Article
View All Connect Biopharma Holdings Limited News